

Pharmaceuticals

Target price: Rs455

Earnings revision

(%)	FY24E	FY25E
Sales	1.4	2.4
EBITDA	0.9	3.1

Target price revision

Rs455 from Rs435

Shareholding pattern

	Sep '22	Dec '22	Mar '23
Promoters	55.0	55.0	55.0
Institutional investors	40.1	39.2	39.2
MFs and other	15.3	13.7	13.3
Insurance	0.4	0.5	0.4
FII	24.4	25.0	25.5
Others	4.2	5.8	5.8

Source: BSE India

ESG disclosure score

Year	2021	2022	Chg
ESG score	NA	NA	NA
Environment	NA	NA	NA
Social	NA	NA	NA
Governance	NA	NA	NA

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: Bloomberg, I-sec research

Research Analysts:

Abdulkader Puranwala

abdulkader.puranwala@icicisecurities.com
+91 22 6807 7339

Rohan John

rohan.john@icicisecurities.com
+91 22 6807 7453

Vijaya Diagnostic Centre

BUY

Maintained

Rs386

Non-covid patient footfall sturdy

Vijaya Diagnostic Centre's (Vijaya) Q4FY23 performance was driven by a steady 22.4% YoY growth in non-covid business, while covid business' contribution fell to 1% (15% in Q4FY22). Overheads of new centres impacted EBITDA margin to a small extent though, at 40.6% in Q4, it continues to be better than that of most of listed peers. Strong B2C franchise (95% of revenue in Q4FY23) and a dominant presence in radiology has helped the company command better margins. Traction in new centres at Tirupati and Rajamundhry, coupled with further expansion in the east (especially Kolkata), may drive medium- to long-term growth. Maintain BUY with a revised target price of Rs455/share (earlier: Rs435).

- ▶ **Business review:** Non-covid revenues were up 22.4% YoY (+7.4% QoQ) driven by both radiology and pathology segments. Radiology contribution improved to ~36% vs 31% in Q4FY22 (36% in Q3FY23). Covid revenues contributed just 1% in Q4FY23 vs 15%/1% in Q4FY22/Q3FY23. Wellness share in Q4FY23 was up at 13.4% against 8.4% in Q4FY22. Test volumes were up 10.6% YoY with healthy growth in non-covid and wellness segments. However, patient volumes declined 16.7% YoY due to decline in covid cases. Average realisation on tests was down 5.7% YoY and 1.5% QoQ while that on patients improved by 24.1% YoY and 2.7% QoQ. We expect 15% CAGR in patient volume over FY23-FY25E driven by the addition of new centres and increasing footfalls. Gross margin expanded 250bps YoY (-80bps QoQ) to 87.2% led by higher radiology contribution. EBITDA margin was down 60bps at 40.6% due to incremental expenses of new centres. PAT grew 15.8% YoY to Rs275mn due to change in depreciation accounting.
- ▶ **Concall highlights:** 1) **Guidance:** Revenue growth of 15% for FY24. Existing centres to contribute ~10-11% growth. ii) Maintain EBITDA margin of ~40% in FY24. iii) Expect EBITDA breakeven for Tirupati to be faster than Rajamundhry (took ~6 months) iv) Capex expenditure of Rs750mn-800mn for FY24. 2) **Pricing:** i) Price increases were taken in 40-50 tests for a few geographies (~0.8-1% of revenues). ii) No intention to raise prices across the test menu. iii) New centre to commercialize in North Kolkata in the next couple of months.
- ▶ **Outlook:** With higher contribution from radiology and B2C focus, Vijaya commands best-in-industry EBITDA margin, which we believe would continue and sustain above 40%. We expect a revenue CAGR of 16.3% over FY23-FY25E with EBITDA CAGR at 18.9%. Despite continuous expansion, we expect the company to generate free cashflow of ~Rs2.8bn over FY23-FY25E.
- ▶ **Valuation:** We raise our revenue estimates by ~1-2% over FY24E-FY25E to factor-in the healthy growth in volumes and network expansion. We also increase our EPS estimates to account for the change in depreciation methodology from WDV to SLM. Retain **BUY** with a revised DCF-based target price of Rs455/share (earlier: Rs435). **Key downside risks:** Slowdown in growth in southern region, and regulatory hurdles.

Market Cap	Rs39.3bn/US\$476mn
Reuters/Bloomberg	VIJAYA IN
Shares Outstanding (mn)	102.1
52-week Range (Rs)	489/300
Free Float (%)	45.0
FII (%)	25.5
Daily Volume (USD/000)	1,515
Absolute Return 3m (%)	2.1
Absolute Return 12m (%)	2.6
Sensex Return 3m (%)	7.2
Sensex Return 12m (%)	14.1

Year to Mar	FY22	FY23	FY24E	FY25E
Revenue (Rs mn)	4,624	4,592	5,351	6,215
Net Income (Rs mn)	1,097	846	1,095	1,381
EPS (Rs)	10.7	8.3	10.7	13.5
% Chg YoY	30.2	(22.8)	29.3	26.2
P/E (x)	35.9	46.6	36.0	28.5
CEPS (Rs)	15.9	14.3	16.6	20.0
EV/E (x)	19.0	21.6	17.9	14.4
Dividend Yield (%)	-	-	-	-
RoCE (%)	20.9	13.7	14.8	15.8
RoE (%)	26.5	16.7	18.3	19.1

Table 1: Q4FY23 performance

(Rs mn, year ending March 31)


	Q4FY23	Q4FY22	YoY % Chg	Q3FY23	QoQ % Chg
Net Sales	1,210	1,162	4.1	1,131	7.0
Gross Profit	1,055	983	7.2	995	6.0
Gross margins (%)	87.2	84.6	250bps	87.9	(80bps)
EBITDA	491	479	2.6	443	10.9
EBITDA margins (%)	40.6	41.2	(60bps)	39.1	140bps
Other income	45	32	41.6	36	27.0
PBIDT	536	511	5.0	478	12.1
Depreciation	114	153	(25.7)	203	(44.0)
Interest	58	43	33.1	55	4.1
Extra ordinary income/ (exp.)	-	-	-	-	-
PBT	365	315	16.1	220	65.8
Tax	88	75	16.2	56	57.7
Minority Interest	2	2	36.7	1	152.9
Reported PAT	275	237	15.8	164	68.0
Adjusted PAT	275	237	15.8	164	68.0

Source: Company data, I-Sec research


Table 2: Metrics overview

	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	YoY % Chg	QoQ % Chg
No of tests (mn)	2.2	2.4	2.3	2.5	2.2	2.6	2.5	2.7	10.6	8.8
No of Patient/Footfall (mn)	0.9	0.9	0.9	1.0	0.8	0.9	0.8	0.8	(16.7)	3.9
Rev per test	562	477	477.5	474	469.0	459	454	447	(5.7)	(1.5)
Rev per patient	1,299	1,295	1,303.0	1,212	1,395.0	1418	1,464	1,504	24.1	2.7


Source: Company data, I-Sec research

Chart 1: Consistent volume growth in patients and tests


Source: Company data, I-Sec research.

Chart 2: Pathology vs radiology split (FY23)


Source: Company data, I-Sec research.

Chart 2: Revenue CAGR likely at 16.3% over FY23-FY25E


Source: Company data, I-Sec research

Chart 3: EBITDA margin to improve 180bps to ~41% due to operating leverage

Source: Company data, I-Sec research

Chart 4: Vijaya to maintain superior RoCE

Source: Company data, I-Sec research

Chart 5: Net profit CAGR expected at 27.8% over FY23-FY25E


Source: Company data, I-Sec research

Valuations

We expect revenues to grow 16.3% over FY23-FY25E mainly due to addition of new centres and increasing footfalls; however, realisation in the near term is likely to be under pressure mainly due to incremental competition. We expect EBITDA CAGR of 18.9% over FY23-FY25E with 180bps improvement in margins due to operating leverage. Despite continuous expansion, the company is likely to generate free cashflow of ~Rs2.8bn over FY23-FY25E. Further, we expect RoCE to remain at ~16% (RoIC at ~28%) despite continued deeper network expansion in key geographies. Company's dominant position in south India, B2C focus, strong brand equity in the organised diagnostics market and continuing financial growth across parameters, are likely to help command premium valuations, in our view.

The stock currently trades at valuations of 36x FY24E and 28.5x FY25E earnings and EV/EBITDA multiple of 17.9x FY23E and 14.4x FY24E. We remain positive on Vijaya, given its dominant position in south India, B2C focus with continuous deeper network expansion in its dominant geographies, along with supportive macro factors and expectations of a faster shift of the market toward organised players. Maintain **BUY** with a revised DCF-based target price of Rs455/share (earlier: Rs435), implying 33.6x FY25E EPS and 17.1x FY25E EV/EBITDA.

Chart 6: 1-year forward EV/EBITDA



Source: Company data, I-Sec research

Price chart



Source: Bloomberg

Financial summary (consolidated)

Table 3: Profit & Loss statement

(Rs mn, year ending March 31)

	FY22	FY23	FY24E	FY25E
Total Net Revenue	4,624	4,592	5,351	6,215
YoY Growth%	22.7	(0.7)	16.5	16.2
Total Op. Exp.	2,587	2,772	3,209	3,641
EBITDA	2,037	1,820	2,141	2,574
Margins %	44.1	39.6	40.0	41.4
YoY Growth%	22.7	(10.6)	17.6	20.2
Depreciation & Amortization	527	617	596	660
EBIT	1,510	1,203	1,546	1,914
Other Income	128	142	156	171
Interest	165	209	230	230
EO Items	-	-	-	-
PBT	1,474	1,135	1,471	1,855
Tax	367	283	371	467
Tax Rate (%)	24.9	24.9	25.2	25.2
Minority Interest	10	6	6	6
Reported PAT	1,097	846	1,095	1,381
Adj PAT	1,097	846	1,095	1,381
Net Margins (%)	23.7	18.4	20.5	22.2

Source: Company data, I-Sec research

Table 4: Balance sheet

(Rs mn, year ending March 31)

	FY22	FY23	FY24E	FY25E
Paid up Capital	102	102	102	102
Reserves & Surplus	4,580	5,345	6,440	7,821
Total Equity	4,682	5,447	6,542	7,923
Minority Interest	13	19	25	31
Total Debt	1,835	2,476	2,476	2,476
Deferred Liabilities	(89)	(82)	(82)	(82)
Capital Employed	6,441	7,859	8,960	10,347
Current Liabilities & Prov	605	592	687	789
Total Liabilities	7,046	8,452	9,647	11,136
Net Fixed Assets	4,046	5,516	5,721	5,810
Investments	0	0	0	0
Inventory	43	20	25	29
Debtors	98	95	111	128
Other Current Assets	393	265	280	296
Cash and Equivalents	2,466	2,554	3,511	4,872
Total Cur. Assets	2,999	2,935	3,926	5,325
Total Assets	7,046	8,452	9,647	11,136

Source: Company data, I-Sec research

Table 5: Cashflow statement

(Rs mn, year ending March 31)

	FY22	FY23	FY24E	FY25E
PBT	1,474	1,135	1,471	1,855
Depreciation	527	617	596	660
Net Chg in WC	(50)	93	23	22
Taxes	(399)	(262)	(371)	(467)
Others	29	64	267	272
CFO	1,580	1,646	1,987	2,342
Capex	(1,209)	(1,246)	(800)	(750)
Net Investments made	(127)	86	-	-
Others	106	64	-	-
CFI	(1,231)	(1,096)	(800)	(750)
Change in Share capital	-	12	-	-
Change in Debts	(286)	(328)	-	-
Div. & Div Tax	-	(102)	-	-
Others	(83)	(891)	(230)	(230)
CFF	(368)	(1,310)	(230)	(230)
Total Cash Generated	(19)	(759)	956	1,361
Cash Opening Balance	1,942	1,924	1,164	2,121
Cash Closing Balance	1,924	1,164	2,121	3,482

Source: Company data, I-Sec research

Table 6: Key ratios

(Year ending March 31)

	FY22	FY23	FY24E	FY25E
Adj EPS	10.7	8.3	10.7	13.5
YoY Growth%	30.2	(22.8)	29.3	26.2
Cash EPS	15.9	14.3	16.6	20.0
EBITDA (%)	44.1	39.6	40.0	41.4
NPM (%)	23.7	18.4	20.5	22.2
Net Debt to Equity (x)	(0.1)	(0.0)	(0.2)	(0.3)
P/E (x)	35.9	46.6	36.0	28.5
EV/EBITDA (x)	19.0	21.6	17.9	14.4
P/BV (x)	8.4	7.2	6.0	5.0
EV/Sales (x)	8.4	8.6	7.2	6.0
ROCE (%)	20.9	13.7	14.8	15.8
ROE (%)	26.5	16.7	18.3	19.1
ROIC (%)	34.8	20.9	22.9	27.6
Book Value (Rs)	45.9	53.4	64.1	77.6
DPS (Rs)	-	1.0	-	-
Dividend Payout (%)	-	12.1	-	-
Div Yield (%)	-	-	-	-
F.Asset Turnover Ratio	1.4	1.0	1.0	1.1
Avg Collection days	6	8	7	7
Avg Inventory days	3	3	2	2

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala MBA (Finance); Rohan John; MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Anoop Goyal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Prabodh Avadhort Email address: headservicequality@icicidirect.com Contact Number: 18601231122
